{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:11:15Z","timestamp":1780402275289,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019438","name":"Nederlandse Hersenbank","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020251","name":"Nederlands Herseninstituut","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020251","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2025.e00779","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T22:58:10Z","timestamp":1762383490000},"page":"e00779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Exidavnemab binds to aggregated \u03b1-synuclein in human brains affected by \u03b1-synucleinopathies"],"prefix":"10.1016","volume":"23","author":[{"given":"Olof","family":"Zachrisson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Johannesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"S\u00f6derberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Sunnemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily B.","family":"Button","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Odergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunilla","family":"Osswald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lannfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"F\u00e4lting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00779_bib1","article-title":"Cognition deficits in Parkinson\u2019s disease: mechanisms and treatment","volume":"2020","author":"Fang","year":"2020","journal-title":"Parkinsons Dis"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00779_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s40120-024-00620-x","article-title":"Differentiating prodromal dementia with Lewy bodies from prodromal Alzheimer\u2019s disease: a pragmatic review for clinicians","volume":"13","author":"Wyman-Chick","year":"2024","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00779_bib3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3233\/JAD-170397","article-title":"Multiple system atrophy: an oligodendroglioneural synucleinopathy","volume":"62","author":"Jellinger","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00779_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030599","article-title":"Heterogeneity of multiple system atrophy: an update","volume":"10","author":"Jellinger","year":"2022","journal-title":"Biomedicines"},{"issue":"5321","key":"10.1016\/j.neurot.2025.e00779_bib5","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"issue":"6645","key":"10.1016\/j.neurot.2025.e00779_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00779_bib7","first-page":"879","article-title":"Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson\u2019s disease and dementia with Lewy bodies","volume":"152","author":"Baba","year":"1998","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00779_bib8","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00779_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.40.1.1","article-title":"The Lewy body variant of Alzheimer\u2019s disease: a clinical and pathologic entity","volume":"40","author":"Hansen","year":"1990","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00779_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/ana.23659","article-title":"Neuropathologic substrates of Parkinson disease dementia","volume":"72","author":"Irwin","year":"2012","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00779_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3233\/JPD-225111","article-title":"Proposal for a biologic staging system of Parkinson\u2019s disease","volume":"13","author":"Chahine","year":"2023","journal-title":"J Parkinsons Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00779_bib12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"H\u00f6glinger","year":"2024","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00779_bib13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410440324","article-title":"Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein","volume":"44","author":"Tu","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00779_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pneurobio.2014.02.007","article-title":"Towards translational therapies for multiple system atrophy","volume":"118","author":"Kuzdas-Wood","year":"2014","journal-title":"Prog Neurobiol"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00779_bib15","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1093\/brain\/awaf030","article-title":"Neuronal \u03b1-synuclein toxicity is the key driver of neurodegeneration in multiple system atrophy","volume":"148","author":"Wiseman","year":"2025","journal-title":"Brain"},{"issue":"5999","key":"10.1016\/j.neurot.2025.e00779_bib16","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","article-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","volume":"329","author":"Burr\u00e9","year":"2010","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00779_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/jnc.14810","article-title":"The physiological role of \u03b1-synuclein and its relationship to Parkinson\u2019s disease","volume":"150","author":"Sulzer","year":"2019","journal-title":"J Neurochem"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00779_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"alpha-Synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat Cell Biol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00779_bib19","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1073\/pnas.0711053105","article-title":"The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease","volume":"105","author":"Gorbatyuk","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00779_bib20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","article-title":"The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson\u2019s disease","volume":"37","author":"Sharon","year":"2003","journal-title":"Neuron"},{"issue":"Pt 4","key":"10.1016\/j.neurot.2025.e00779_bib21","first-page":"1093","article-title":"Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies","volume":"132","author":"Paleologou","year":"2009","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00779_bib22","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1093\/brain\/awx275","article-title":"Synaptic phosphorylated \u03b1-synuclein in dementia with Lewy bodies","volume":"140","author":"Colom-Cadena","year":"2017","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00779_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson\u2019s disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.neurot.2025.e00779_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1436262","article-title":"\u201cPrion-like\u201d seeding and propagation of oligomeric protein assemblies in neurodegenerative disorders","volume":"18","author":"Zampar","year":"2024","journal-title":"Front Neurosci"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00779_bib25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.molmed.2020.03.012","article-title":"Cell-to-cell transmission of tau and \u03b1-synuclein","volume":"26","author":"Uemura","year":"2020","journal-title":"Trends Mol Med"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00779_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00779_bib27","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1007\/s13311-020-00890-x","article-title":"Current management and emerging therapies in multiple system atrophy","volume":"17","author":"Burns","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00779_bib28","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7556","key":"10.1016\/j.neurot.2025.e00779_bib29","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature14547","article-title":"\u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration","volume":"522","author":"Peelaerts","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.neurot.2025.e00779_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104587","article-title":"Immunotherapy in Parkinson\u2019s disease: current status and future directions","volume":"132","author":"Chatterjee","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00779_bib31","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/imt.13.162","article-title":"Immunotherapy targeting \u03b1-synuclein, with relevance for future treatment of Parkinson\u2019s disease and other Lewy body disorders","volume":"6","author":"Lindstr\u00f6m","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.neurot.2025.e00779_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nbd.2014.05.009","article-title":"Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice","volume":"69","author":"Lindstr\u00f6m","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00779_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105543","article-title":"ABBV-0805, a novel antibody selective for soluble aggregated \u03b1-synuclein, prolongs lifespan and prevents buildup of \u03b1-synuclein pathology in mouse models of Parkinson\u2019s disease","volume":"161","author":"Nordstr\u00f6m","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.neurot.2025.e00779_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fnins.2018.00452","article-title":"Region-specific effects of immunotherapy with antibodies targeting \u03b1-synuclein in a transgenic model of synucleinopathy","volume":"12","author":"Kallab","year":"2018","journal-title":"Front Neurosci"},{"issue":"11","key":"10.1016\/j.neurot.2025.e00779_bib35","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/jcph.6103","article-title":"Safety, tolerability, and pharmacokinetics of single doses of exidavnemab (BAN0805), an anti-\u03b1-synuclein antibody, in healthy Western, Caucasian, Japanese, and Han Chinese adults","volume":"64","author":"Bostr\u00f6m","year":"2024","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00779_bib36","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s13311-022-01288-7","article-title":"Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: a biological perspective","volume":"19","author":"Knecht","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00779_bib37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00415-024-12770-x","article-title":"An update on immune-based alpha-synuclein trials in Parkinson\u2019s disease","volume":"272","author":"Alfaidi","year":"2024","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00779_bib38","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","article-title":"Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00779_bib39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","article-title":"Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease","volume":"30","author":"Pagano","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.neurot.2025.e00779_bib40","article-title":"A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson\u2019s disease (PADOVA): rationale, design, and baseline data","volume":"132","author":"Nikolcheva","year":"2025","journal-title":"Parkinsonism Relat Disorders"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00779_bib41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41531-024-00849-1","article-title":"Rational selection of the monoclonal \u03b1-synuclein antibody amlenetug (Lu AF82422) for the treatment of \u03b1-synucleinopathies","volume":"11","author":"Kallunki","year":"2025","journal-title":"npj Parkinson\u2019s Dis"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00779_bib42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jnc.12175","article-title":"Monoclonal antibodies selective for \u03b1-synuclein oligomers\/protofibrils recognize brain pathology in Lewy body disorders and \u03b1-synuclein transgenic mice with the disease-causing A30P mutation","volume":"126","author":"Fagerqvist","year":"2013","journal-title":"J Neurochem"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00779_bib43","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13195-022-01150-0","article-title":"Alpha-synuclein: a pathological factor with A\u03b2 and tau and biomarker in Alzheimer\u2019s disease","volume":"14","author":"Shim","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00779_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s40478-022-01440-6","article-title":"Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson\u2019s disease","volume":"10","author":"Sekiya","year":"2022","journal-title":"Acta Neuropathol Commun"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00779_bib45","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00005072-199804000-00005","article-title":"Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson\u2019s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity","volume":"57","author":"Irizarry","year":"1998","journal-title":"J Neuropathol Exp Neurol"},{"issue":"10","key":"10.1016\/j.neurot.2025.e00779_bib46","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","article-title":"Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial","volume":"75","author":"Jankovic","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00779_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104582","article-title":"Preclinical development of a high affinity \u03b1-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular \u03b1-synuclein and attenuate \u03b1-synuclein spreading in vivo","volume":"132","author":"Schofield","year":"2019","journal-title":"Neurobiol Dis"},{"issue":"7","key":"10.1016\/j.neurot.2025.e00779_bib48","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.tins.2024.05.005","article-title":"Physiological roles of \u03b1-synuclein serine-129 phosphorylation - not an oxymoron","volume":"47","author":"Ramalingam","year":"2024","journal-title":"Trends Neurosci"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00779_bib49","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00779_bib50","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/jnen\/59.8.733","article-title":"Sequence of Abeta-protein deposition in the human medial temporal lobe","volume":"59","author":"Thal","year":"2000","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2025.e00779_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:08:59Z","timestamp":1774858139000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747925002570"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00779","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exidavnemab binds to aggregated \u03b1-synuclein in human brains affected by \u03b1-synucleinopathies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00779"}}